We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rivastigmine Capsules in Patients With Probable Vascular Dementia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00130338
First Posted: August 15, 2005
Last Update Posted: March 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis
August 11, 2005
August 15, 2005
March 28, 2017
February 2002
May 2006   (Final data collection date for primary outcome measure)
Safety and tolerability of rivastigmine for up to 52 weeks of treatment in patients with VaD and probable VaD
Not Provided
Complete list of historical versions of study NCT00130338 on ClinicalTrials.gov Archive Site
52 week's treatment with rivastigmine on cognition, activities of daily living, behavior and clinical staging in patients with VaD and probable VaD
Not Provided
Not Provided
Not Provided
 
Rivastigmine Capsules in Patients With Probable Vascular Dementia
An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Vascular Dementia
Drug: Rivastigmine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
521
May 2006
May 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who complete the double-blind treatment phase or those who have dropped out early in the study, but have returned for all the remaining scheduled efficacy assessments (retrieved drop-out patients) without significant protocol violations are eligible to participate.

Exclusion Criteria:

  • Retrieved drop-out patients, who have been treated with other cholinergic drugs during the past 4 weeks
Sexes Eligible for Study: All
50 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00130338
CENA713BIA05E1
Not Provided
Not Provided
Not Provided
Novartis
Novartis
Not Provided
Not Provided
Novartis
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP